A Two Part Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Renal Safety, Tolerability and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function on Angiotensin Receptor Blockers
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2018
At a glance
- Drugs LHW 090 (Primary)
- Indications Kidney disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 13 Sep 2017 Planned End Date changed from 2 Apr 2018 to 6 Aug 2018.
- 13 Sep 2017 Planned primary completion date changed from 2 Apr 2018 to 6 Aug 2018.
- 21 Mar 2017 Planned End Date changed from 28 Feb 2018 to 2 Apr 2018.